2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France

被引：31

作者：

Franchet, Camille ^{[1
]}

Djerroudi, Lounes ^{[1
]}

Maran-Gonzalez, Aurelie ^{[1
]}

Abramovici, Olivia ^{[1
]}

Antoine, Martine ^{[1
]}

Becette, Veronique ^{[1
]}

Berghian, Anca ^{[1
]}

Blanc-Fournier, Cecile ^{[1
]}

Brabencova, Eva ^{[1
]}

Charafe-Jauffret, Emmanuelle ^{[1
]}

Chenard, Marie-Pierre ^{[1
]}

Dauplat, Marie-Melanie ^{[1
]}

Delree, Paul ^{[1
]}

Duprez-Paumier, Raphaelle ^{[1
]}

Fleury, Clemence ^{[1
]}

Ghnassia, Jean-Pierre ^{[1
]}

Haudebourg, Juliette ^{[1
]}

Leroux, Agnes ^{[1
]}

MacGrogan, Gaetan ^{[1
]}

Mathieu, Marie-Christine ^{[1
]}

Michenet, Patrick ^{[1
]}

Penault-Llorca, Frederique ^{[1
]}

Poulet, Bruno ^{[1
]}

Robin, Yves Marie ^{[1
]}

Roger, Pascal ^{[1
]}

Russ, Elisabeth ^{[1
]}

Tixier, Lucie ^{[1
]}

Treilleux, Isabelle ^{[1
]}

Valent, Alexander ^{[1
]}

Verriele, Veronique ^{[1
]}

Vincent-Salomon, Anne ^{[1
]}

Arnould, Laurent ^{[1
]}

Lacroix-Triki, Magali ^{[1
]}

机构：

[1] Grp Etud Facteurs Pronost Immunohistochim Canc Se, Unicanc, 101 Rue Tolbiac, F-75654 Paris 13, France

来源：

ANNALES DE PATHOLOGIE | 2021年 / 41卷 / 06期

关键词：

Breast cancer; Guidelines; HER2; Immunohistochemistry; In situ hybridization; ERBB2; PATHOLOGICAL COMPLETE RESPONSE; IN-SITU HYBRIDIZATION; FACTOR RECEPTOR 2; GENE AMPLIFICATION; ADJUVANT TRASTUZUMAB; ESTROGEN-RECEPTOR; OPEN-LABEL; MULTICENTER; EXPRESSION; MUTATIONS;

D O I：

10.1016/j.annpat.2021.07.014

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

The last international guidelines on HER2 determination in breast cancer have been updated in 2018 by the American Society of Clinical Oncology and College of American Pathologists, on the basis of a twenty-year practice and results of numerous clinical trials. Moreover, the emerging HER2-low concept for 1+ and 2+ non amplified breast cancers lead to refine French practices for HER2 status assessment. The GEFPICS group, composed of expert pathologists, herein presents the latest French recommendations for HER2 status evaluation in breast cancer, taking into account the ASCO/CAP guidelines and introducing the HER2-low concept. In the era of personalized medicine, HER2 status assessment remains one of the most important biomarkers in breast cancer and its quality guaranties the optimal patients' care. French pathologists' commitment in theranostic biomarker quality is more than ever required to provide the most efficient cares in oncology. (C) 2021 Elsevier Masson SAS. All rights reserved.

引用

页码：507 / 520

页数：14

共 50 条

[41] Accurate Assessment of HER2 Gene Status for Invasive Component of Breast Cancer by Combination of Immunohistochemistry and Chromogenic In Situ Hybridization
聂秀
贺骏
李燕
潘丹珍
潘华雄
翁密霞
杨秀萍
刘春萍
黄韬
Journal of Huazhong University of Science and Technology(Medical Sciences), 2013, 33 (03) : 379 - 384
[42] Accurate assessment of HER2 gene status for invasive component of breast cancer by combination of immunohistochemistry and chromogenic In Situ hybridization
Xiu Nie
Jun He
Yan Li
Dan-zhen Pan
Hua-xiong Pan
Mi-xia Weng
Xiu-ping Yang
Chun-ping Liu
Tao Huang
Journal of Huazhong University of Science and Technology [Medical Sciences], 2013, 33 : 379 - 384
[43] Assessment of HER2 status in invasive breast cancer with increased centromere 17 copy number by fluorescence in situ hybridization
Jang, Min Hye
Kim, Eun Joo
Kim, Hyun Jeong
Park, So Yeon
CANCER RESEARCH, 2015, 75
[44] Accurate assessment of HER2 gene status for invasive component of breast cancer by combination of immunohistochemistry and chromogenic In Situ hybridization
Nie, Xiu
He, Jun
Li, Yan
Pan, Dan-zhen
Pan, Hua-xiong
Weng, Mi-xia
Yang, Xiu-ping
Liu, Chun-ping
Huang, Tao
JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES, 2013, 33 (03) : 379 - 384
[45] Accurate Assessment of HER2 Gene Status for Invasive Component of Breast Cancer by Combination of Immunohistochemistry and Chromogenic In Situ Hybridization
聂秀
贺骏
李燕
潘丹珍
潘华雄
翁密霞
杨秀萍
刘春萍
黄韬
Current Medical Science, 2013, (03) : 379 - 384
[46] Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer
Mohammed, Zahra M. A.
Going, James J.
McMillan, Donald C.
Orange, Clare
Mallon, Elizabeth
Doughty, Julie C.
Edwards, Joanne
HISTOPATHOLOGY, 2012, 61 (04) : 675 - 684
[47] Histologic analysis according to HER2 gene status in HER2 2+invasive breast cancer: a study of 280 cases comparing ASCO/CAP 2013 and 2018 guideline recommendations
Hwang, Hye Won
Hong, Soon Auck
Nam, Seok Jin
Kim, Seok Won
Lee, Jeong Eon
Yu, Jong-Han
Lee, Se Kyung
Cho, Soo Youn
Cho, Eun Yoon
VIRCHOWS ARCHIV, 2022, 480 (04) : 749 - 758
[48] Impact of the Change of the Criteria for HER2 Immunohistochemistry Interpretation on HER2 Status in Breast Cancer
Harada, Shuko
Shen, Dejun
Wei, Shi
MODERN PATHOLOGY, 2016, 29 : 44A - 44A
[49] Impact of the Change of the Criteria for HER2 Immunohistochemistry Interpretation on HER2 Status in Breast Cancer
Harada, Shuko
Shen, Dejun
Wei, Shi
LABORATORY INVESTIGATION, 2016, 96 : 44A - 44A
[50] Her2 gene status in breast"in situ" and invasive ductal carcinoma
Cozaru, G. C.
Mitroi, A. F.
Aschie, M.
Brinzan, C. S.
Poinareanu, I.
EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 968 - 969

← 1 2 3 4 5 →